← Back to Search
The Diagnostic Utility Of P16 FISH And GLUT-1 Immunohistochemical Analysis In Mesothelial Proliferations.
S. Monaco, Y. Shuai, Mona Bansal, A. Krasinskas, S. Dacic
Published 2011 · Biology, Medicine
Download PDFAnalyze on Scholarcy
Two promising ancillary tests used in the diagnosis of mesothelioma include GLUT-1 immunohistochemical analysis and fluorescence in situ hybridization (FISH) testing for the p16 deletion. This study compared the diagnostic usefulness of p16 FISH and GLUT-1 immunohistochemical analysis in the diagnosis of mesothelial proliferations in 158 cases with a diagnosis of benign (45.4%), atypical (10.4%), or malignant/mesothelioma (44.2%). Of the 70 benign cases, none had a deletion of p16 and 5 cases (7%) were positive for GLUT-1. Of the 68 mesotheliomas, 40 (59%) had a deletion of p16 (sensitivity, 59%; specificity, 100%) and 27 (40%) were positive for GLUT-1 (sensitivity, 40%; specificity, 93%). GLUT-1 showed lower sensitivity in pleural (56% vs 70%) and peritoneal (29% vs 51%) mesotheliomas (P = .004). Our results demonstrate that p16 FISH is a more sensitive and specific test than GLUT-1 immunohistochemical analysis and can be a more reliable ancillary tool to support the diagnosis of mesothelioma.
This paper references
The utility of GLUT‐1 immunolocalization in cell blocks
V. Chandan (2006)
K. R. Casey (1981)
Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia.
A. Clavo (1995)
The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions
F. Hasteh (2010)
Differential subcellular distribution of glucose transporters GLUT1–6 and GLUT9 in human cancer: Ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues
A. Godoy (2006)
Distinction between carcinoma cells and mesothelial cells in serous effusions. Usefulness of immunohistochemistry.
R. Tickman (1990)
The utility of GLUT1 immunolocalization in cell blocks : an adjunct to the fine needle aspiration diagnosis of cystic squamous lesions of the head and neck
VS Chandan (2006)
Gene copy number analysis in malignant pleural mesothelioma using oligonucleotide array CGH
P. M. Lindholm (2007)
Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas
S. Dacic (2008)
Correspondence re: Ito T, Noguchi Y, Satoh S, Hayashi H, Inayama Y, Kitamura H: Expression of facilitative glucose transporter isoforms in lung carcinomas: its relation to histologic type, differentiation grade, and tumor stage. Mod Pathol 1998; 11:437-443.
S. Zador (1998)
The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma.
A. Renshaw (1997)
Asbestos: scientific developments and implications for public policy.
B. Mossman (1990)
Usefulness of EMA, GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids.
J. Shen (2009)
Reactive and Neoplastic Serosal Tissue: A Light-Microscopic, Ultrastructural, and Immunocytochemical Study
J. W. Bolen (1986)
Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas
S. Chiosea (2008)
The role of immunolocalization of CD 57 and GLUT1 in cell blocks in fine needle aspiration diagnosis of papillary thyroid carcinoma
VS Chandan (2006)
Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer.
R. Brown (1999)
Advances in malignant mesothelioma.
B. Robinson (2005)
The value of epithelial membrane antigen expression in separating benign mesothelial proliferation from malignant mesothelioma: A comparative study
R. Saad (2005)
Glucose transporter protein 1 expression in mucoepidermoid carcinoma of salivary gland: correlation with grade of malignancy
A. P. Demasi (2010)
GLUT-1 and GLUT3 as potential prognostic markers for oral squamous cell carcinoma
Fr Ayala (2010)
Structure, function, and regulation of the mammalian facilitative glucose transporter gene family.
A. L. Olson (1996)
The role of immunolocalization of CD57 and GLUT‐1 in cell blocks in fine‐needle aspiration diagnosis of papillary thyroid carcinoma
V. Chandan (2006)
Mechanisms of carcinogenesis and clinical features of asbestos-associated cancers.
B. Mossman (1996)
Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas.
P. Illei (2003)
Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma
Y. Kato (2007)
Glut1 and Glut3 as Potential Prognostic Markers for Oral Squamous Cell Carcinoma
F. Ayala (2010)
Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach.
E. R. Delong (1988)
Immunocytochemical profile of benign and carcinomatous effusions. A practical approach to difficult diagnosis.
J. M. Esteban (1990)
Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003.
B. Price (2004)
Expression of facilitative glucose transporter isoforms in lung carcinomas: its relation to histologic type, differentiation grade, and tumor stage.
T. Ito (1998)
[Malignant pleural mesothelioma].
Q. Kong (1983)
The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet‐derived growth factor‐receptor, P‐glycoprotein and Bcl‐2
R. Attanoos (2003)
American Society for Clinical Pathology Anatomic Pathology / Original Article
The Separation of Benign and Malignant Mesothelial Proliferations
A. Churg (2012)
Overexpression of glut1 and glut3 in stage I nonsmall cell lung carcinoma is Associated with poor survival
M. Younes (1997)
CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival
A. Krasinskas (2010)
GLUT - 1 and GLUT 3 as potential prognostic markers for oral squamous cell carcinoma
FR Ayala (2010)
GLUT1 glucose transporter: a highly sensitive marker of malignancy in body cavity effusions.
D. Burstein (1998)
Genomic events associated with progression of pleural malignant mesothelioma
S. V. Ivanov (2009)
Genomic profiling of malignant pleural mesothelioma with array‐based comparative genomic hybridization shows frequent non‐random chromosomal alteration regions including JUN amplification on 1p32
T. Taniguchi (2007)
Glucose Transporter Glut-1 Is of Limited Value for Detecting Breast Carcinoma in Serous Effusions
R. Zimmerman (2001)
This paper is referenced by
Zytopathologische Ergussdiagnostik in der berufsgenossenschaftlichen Begutachtung von Asbest-assoziierten malignen Mesotheliomen und Lungenkarzinomen Pleural Effusion Cytology of Asbestos-Associated Malignant Mesothelioma and Lung Carcinoma in the Diagnosis of Occupational Diseases by the Statutory
S. Biesterfeld (2014)
New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet?
A. Churg (2016)
Reactive Mesothelial Hyperplasia
S. Ali (2012)
Utility of glucose transporter 1 in the distinction of benign and malignant thoracic and abdominal mesothelial lesions.
S. Lagana (2012)
Cytologic Differential Diagnosis of Malignant Mesothelioma and Reactive Mesothelial Cells With FISH Analysis of p16
K. Hiroshima (2016)
The evolving role of effusion cytology in the diagnosis of malignant mesothelioma
A. Paintal (2015)
Utility of immunohistochemistry in the diagnosis of pleuropulmonary and mediastinal cancers: a review and update.
K. Zhang (2014)
Metastatic Tumors of Unknown Origin: Ancillary Testing in Cytologic Specimens.
S. Monaco (2014)
Molecular Genetics of Malignant Mesothelioma
Y. Sekido (2012)
Practical utility of insulin‐like growth factor II mRNA‐binding protein 3, glucose transporter 1, and epithelial membrane antigen for distinguishing malignant mesotheliomas from benign mesothelial proliferations
S. Chang (2014)
Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens
H. Hwang (2016)
Tissue and Circulating Biomarkers in Mesothelioma
Paolo Andrea Zucali (2019)
BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations
Marta Cigognetti (2015)
Pathological and molecular biological approaches to early mesothelioma
T. Tsujimura (2011)
Differential diagnosis of metastatic tumors
T. Elsheikh (2015)
Low homozygous/high heterozygous deletion status by p16 FISH correlates with a better prognostic group than high homozygous deletion status in malignant pleural mesothelioma.
M. Hamasaki (2016)
Molecular markers and new diagnostic methods to differentiate malignant from benign mesothelial pleural proliferations: a literature review.
R. Bruno (2018)
The diagnosis of malignant mesothelioma in effusion cytology
A. Paintal (2013)
Diagnostic usefulness of p16/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis.
D. Wu (2013)
A rare cause of heart failure with preserved ejection fraction: primary pericardial mesothelioma masquerading as pericardial constriction
R. Fernandes (2014)
Application of Immunohistochemistry in the Diagnosis of Pulmonary and Pleural Neoplasms.
J. Woo (2017)
Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group.
A. Husain (2018)
CDKN 2 A FISH in Differentiation of Diffuse Malignant Peritoneal Mesothelioma From Mesothelial Hyperplasia and Epithelial Ovarian Cancer
T. Ito (2015)
BAP1 Immunohistochemistry and p16 FISH to Separate Benign From Malignant Mesothelial Proliferations
B. Sheffield (2015)
A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma
Y. Kinoshita (2018)
Use of p16 FISH for differential diagnosis of mesothelioma in smear preparations
K. Nabeshima (2016)
Recent Advances in the Diagnosis of Malignant Mesothelioma: Focus on Approach in Challenging Cases and in Limited Tissue and Cytologic Samples
S. Monaco (2018)
Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group.
A. Husain (2013)
Localized biphasic malignant peritoneal mesothelioma presenting as a rectal tumor
K. Saisho (2019)
Pleural Malignant Mesothelioma : Signi fi cant Advances Histologic Subtyping of Epithelioid Mesothelioma
F. Galateau-Sallé (2016)
A diagnostically difficult case of a cellular pleural fluid: Morphology, immunohistochemistry, and fluorescence in situ hybridization study
M. Wang (2017)
Use of Anti-Noxa Antibody for Differential Diagnosis between Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia
K. Kushitani (2016)See more